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ORIGINAL ARTICLE
Comparison of the Psychological Impacts of 
Asymptomatic and Symptomatic Cutaneous Diseases: 
Vitiligo and Atopic Dermatitis
Seongmin Noh, Miri Kim, Chang Ook Park, Seung-Kyung Hann1, Sang Ho Oh
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, 1Korea Institute of Vitiligo 
Research and Drs. Woo and Hann’s Skin Center, Seoul, Korea
Background: Vitiligo and atopic dermatitis (AD) are common 
dermatological disorders which may cause significant 
psychological and social distress leading to impaired quality 
of life (QoL) in patients. Objective: We evaluated the degree 
of psychological stress and impairment of QoL in vitiligo 
patients as compared with AD patients and normal controls 
(NCs). Methods: A total of 60 patients from each group and 
60 NCs were enrolled. Five questionnaires on depression 
(Beck depression inventory, BDI), state anxiety (SA) and trait 
anxiety (TA), interaction anxiousness (IAS), private body 
consciousness (PBC) and dermatologic QoL were used. 
Results: The vitiligo patients had a significantly higher level 
of TA (p＜0.01), PBC (p＜0.001) and impaired QoL (p＜ 
0.001) than NCs, but not BDI, SA and IAS. The AD patients 
had significantly higher scores for all five questionnaire items 
compared with NCs. In the comparison between the AD and 
vitiligo groups, all of the indexes except body consciousness 
were higher in AD patients than in vitiligo patients: BDI (p＜ 
0.01), SA (p＜0.05), TA (p＜0.001), IAS (p＜0.01) and 
impaired QoL (p＜0.001). Exposure of vitiligo lesions was 
not a significant variable in the analysis of the contribution of 
clinical variables of vitiligo on psychological stress and QoL. 
Conclusion: Vitiligo, which is not accompanied by any 
symptoms, involves less psychological impact than AD, 
which is accompanied by itching. Compared to NCs, 
however, the elevated general anxiety and body conscious-
ness in patients with vitiligo suggests that they may be more 
concerned with the aggravation of hypopigmented patches 
than difficulties in social interactions. (Ann Dermatol 25(4) 
454∼461, 2013)
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INTRODUCTION
As skin is the largest and most visible part of the human 
body, patients with skin diseases often suffer from psy-
chological stress and impaired quality of life (QoL) due to 
the appearance and subjective symptoms. Psychological 
aspects of skin diseases, including atopic dermatitis (AD), 
psoriasis, urticaria, alopecia areata and vitiligo, have been 
widely investigated. Understanding the psychological as-
pects of skin diseases and implementing psychological 
treatment approaches have been increasingly empha-
sized1-5.
Vitiligo is a depigmenting disorder that affects 0.5% to 1% 
of the total population. The etiology and pathogenesis of 
vitiligo are not well elucidated, but the loss and dys-
function of melanocytes are considered to play a major 
role in its pathogenesis. Vitiligo is characterized by hypo-
pigmented macules of the skin or mucosa, with no 
accompanying subjective symptoms other than the skin 
lesion itself. Although vitiligo does not cause serious 
physical morbidity, patients with the disease may experi-
ence various degrees of psychological stress and altered 
QoL1,2.
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The psychosocial impairments and altered QoL in vitiligo 
patients have been widely reported. It has been reported 
that patients with vitiligo experience emotional distur-
bances such as embarrassment, anger, worry or frust-
ration6,7, and that the disease exerts a negative impact on 
social encounters including sexual relationship8 with an 
increased experience of stigmatization. Patients with viti-
ligo have also been reported to show impaired QoL9-11.
AD is a highly pruritic chronic relapsing skin disease. AD 
patients also experience impaired QoL and severe psy-
chological stress; and moreover, the psychological stress 
can act as an aggravating factor in AD. Thus, psy-
chological stress and AD symptoms such as pruritus and 
sleep loss have a cyclic effect on each other12. In parti-
cular, we have reported in a previous study that, among 
the various kinds of psychological parameters, anxiety was 
strongly associated with the symptoms of AD13.
In this study, we hypothesized that the degree of 
impairment of psychological parameters might be different 
between AD and vitiligo, with AD involving subjective 
symptoms such as pruritus along with skin lesions, unlike 
vitiligo. Previous reports have compared the psychological 
distress in patients with psoriasis and vitiligo11,14-16. In 
these studies, patients with psoriasis were generally 
reported to have a higher level of psychological distress 
than vitiligo patients, except that QoL impairment in 
female patients with vitiligo equalled the impairment 
caused by psoriasis11,15,16. However, to the best of our 
knowledge, no study has compared the psychological 
distress of patients with vitiligo and those with AD. 
Thus in this study, we aimed to compare aspects of the 
psychological stress in vitiligo patients with those of 
normal controls (NCs) and AD patients, using question-
naires that assessed items associated with psychological 
stress and QoL. 
MATERIALS AND METHODS 
Subjects
This study was carried out in Severance Hospital, Yonsei 
University College of Medicine (Seoul, Korea) from March 
2009 to February 2010. A total of 60 vitiligo patients and 
60 AD patients were enrolled in this study. The diagnosis 
of vitiligo was made based on clinical manifestations and 
Wood’s light examination. The diagnosis of AD was based 
on the criteria of Hanifin and Rajka17. Patients taking oral 
corticosteroids or psychotropic drugs, which can affect 
psychological status, were excluded from this study. None 
of the subjects had any other concomitant dermatological 
or psychological disorder. A total of 60 NCs, who did not 
have any dermatological, medical or psychological pro-
blems, were enrolled as a reference group. This study was 
approved by the institutional review board of Yonsei 
University (No 4-2008-0337) and informed consent was 
obtained from each patient (or from the parents of 
paediatric patients), before they participated in the study. 
Information on demographic variables (age and gender) 
and disease-related characteristics (duration of the disease, 
localisation of vitiligo, family history of vitiligo, duration 
of treatment and treatment response) were collected from 
the patients with vitiligo. Information on demographic 
variables (age, gender) of patients with AD was also col-
lected. The clinical severity of AD was graded according 
to the Eczema Area and Severity Index (EASI). 
This study was approved by the Institutional Review Board 
of Yonsei University Health System, Severance Hospital 
(4-2013-0640).
Questionnaires regarding psychological parameters 
and quality of life
The questionnaire consisted of five tests, four of which 
evaluated psychological parameters of depression, anxie-
ty, interaction anxiousness and private body conscious-
ness (PBC), and one that assessed QoL13,18.
The Beck depression inventory second edition (BDI-II), a 
21-question self-report inventory, was used to evaluate the 
existence and severity of symptoms of depression. The 
total value indicated the level and severity of depression. 
BDI-II has been assessed and validated in various medical 
populations19,20, and the Korean version of the BDI was 
previously shown to exhibit good psychometric pro-
perties21.
The Spielberger State-Trait Anxiety Inventory (STAI) is a 
self-report assessment device that measures the state and 
trait anxiety (TA). State anxiety (SA) refers to transitory 
anxiety under certain conditions and at certain times, 
which may be influenced by external factors. TA refers to 
the individual’s anxiety in general and one’s tendency in 
responding to anxiety. The Korean version of STAI has 
demonstrated excellent psychometric properties22.
Interaction Anxiousness Scale (IAS) was constructed to 
determine the tendency to feel nervous in specific situ-
ations. It consists of 15 items of anxiety-evoking situations, 
such as interactions with strangers, authority figures and 
members of the opposite gender. IAS is empirically deri-
ved and has been shown to have good test reliability, 
construct and criterion validity23.
PBC subscale is one of three subscales in the body con-
sciousness questionnaires24. It consists of five items focu-
sing on the symptoms of individuals such as attention to 
dry mouth, hunger and body temperature. Acceptable psy-
chometric properties have been demonstrated24.
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  Male 31 (51.7)
  Female 29 (48.3)
Disease duration (yr)  6.76±7.05
Treatment duration (yr)  1.80±2.66
Exposure 
  Not exposed 11 (18.3)
  Exposed 49 (81.7)
Type 
  Segmental  4 (7.3)
  Vulgaris 34 (61.8)
  Focal 13 (23.6)
  Acrofacial  4 (7.3)
Treatment response 
  Improved within 6 months  3 (5.5)
  No favorable improvement 52 (94.5)
Family history 
  Present   3 (5.5)
  Absent 52 (94.5)
Values are presented as mean±standard deviation or number (%).
Table 3. Demographic and clinical characteristics of patients 
with atopic dermatitis
Characteristic Value 
Age (yr)    32.4±7.9
Sex 
  Male    27 (45.0)
  Female    33 (55.0)
EASI score    19.1±14.3 (2.7∼59.1)
Peripheral blood eosinophil 
count (N/μl)
 623.1±391.4 
Total serum IgE level (kU/L) 2,073.6±1,836.7
Values are presented as mean±standard deviation, number (%), 
or mean±standard deviation (range). EASI: Eczema Area and 
Severity Index, IgE: immunoglobulin E.






Age (yr) 35.1±9.8 32.4±7.9 31.9±11.9 0.206
Sex 0.474
 Male 31 (51.7) 27 (45.0) 25 (41.7)
 Female 29 (48.3) 33 (55.0) 35 (58.3)
Values are presented as mean±standard deviation or number (%).
AD: atopic dermatitis, NC: normal control.
The Dermatology Life Quality Index (DLQI) questionnaire 
of Finlay and Khan25 was used to evaluate QoL of the 
enrolled subjects. DLQI is composed of a 10-question, 
self-report questionnaire, and is one of the most widely 
used dermatology-specific QoL instruments. Since its 
development in 1994, it has been used in many different 
skin diseases, and its validity and reliability have been 
demonstrated26. DLQI is calculated by adding the score of 
each question. The higher the score, the more the QoL is 
impaired.
Statistical analysis
All statistical tests were carried out using PASW Statistics 
software for Windows 18.0 (IBM Co., Armonk, NY, USA). 
We used ANOVA and chi-square test to compare age and 
sex of each group, respectively. A multiple linear regre-
ssion analysis was performed to evaluate the contribution 
of clinical variables to the psychological and QoL indexes. 
Analysis of covariance (ANCOVA) and a multiple linear 
regression analysis were used to compare the values of 
psychological and QoL indexes among vitiligo patients, 
AD patients and NCs, introducing age and gender as 
covariates for adjustment. p＜0.05 were considered sta-
tistically significant. 
RESULTS
Demographic and clinical characteristics of study groups
In the NC group (Table 1), the mean age was 31.9±11.9 
(18 to 59) years, and the ratio of male to female was 1.0：
1.4. There were no significant differences in age and sex 
among the three groups. 
In the vitiligo group (Table 2), the mean age was 35.1±9.8 
years (17 to 50 years), and the mean duration of disease 
was 6.76±7.05 years (1 to 34 years). The ratio of males to 
females was 1.00：0.93. Vitiligo lesions were present on 
exposed areas (head, face, neck and hands) in 83.6% of 
the patients and on non-exposed areas (arms, legs, feet, 
trunk, and genitals) in 16.4%. The most common type of 
vitiligo was vulgaris type (61.8%), followed by focal 
(23.6%), segmental (7.3%) and acrofacial (7.3%) types. 
AD patients (Table 3) had a male to female ratio of 1.00 : 
1.22, and a mean age of 32.4±7.9 years (21.0 to 55.0 
years). The mean EASI score was 19.1±14.3 (2.7 to 59.1). 
Patients with AD were divided into three subgroups based 
on the EASI score: mild, less than 10 (34.1%); moderate, 
10 to 20 (35.4%); and severe, greater than 20 (30.5%)27. 
The mean total serum immunoglobulin E level was 
2,073.6± 1,836.7 (kU/L). 
Effect of clinical variables on psychological parameters 
in the vitiligo group 
In a multiple linear regression analysis with the psy-
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Table 4. Multivariate analysis of factors associated with the 
interaction anxiousness scale (multiple linear regression analysis)




Age* −0.297 −2.134 0.041
Disease duration*   0.383   2.196 0.036




Facial exposure (exposed=0, 
not exposed=1)
  0.042   0.184 0.855
Treatment response 
(yes=0, no=1)
  0.063   0.412 0.683
R2=0.45. *p＜0.05.
Table 5. Factors affecting psychological parameters in com-
parison with normal controls
Model β t p-value
Beck depression inventory
  Gender   0.089   1.251 0.213
  Age**   0.240   3.367 0.001
  Presence of vitiligo   0.083   1.020 0.309
  Presence of AD***   0.368   4.570 0.000
State anxiety
  Gender*   0.164   2.238 0.027
  Age   0.028   0.379 0.705
  Presence of vitiligo   0.130   1.542 0.125
  Presence of AD***   0.341   4.093 0.000
Trait anxiety
  Gender*   0.172   2.534 0.012
  Age*   0.148   2.163 0.032
  Presence of vitiligo**   0.205   2.629 0.009
  Presence of AD***   0.501   6.494 0.000
Interaction anxiousness scale
  Gender −0.018 −0.234 0.816
  Age** −0.228 −3.017 0.003
  Presence of vitiligo −0.060 −0.694 0.489
  Presence of AD*   0.182   2.126 0.035
Private body consciousness
  Gender*   0.167   2.340 0.020
  Age   0.126   1.758 0.081
  Presence of vitiligo***   0.337   4.119 0.000
  Presence of AD***   0.360   4.451 0.000
DLQI
  Gender   0.006   0.097 0.923
  Age*   0.128   2.213 0.028
  Presence of vitiligo***   0.374   5.655 0.000
  Presence of AD***   0.752  11.522 0.000
Gender: 0 if male, 1 if female. AD: atopic dermatitis, DLQI: 
Dermatology Life Quality Index. *p＜0.05, **p＜0.01, ***p＜
0.001.
chological parameters as outcome variables and demo-
graphic and clinical variables as independent variables 
(Table 4), psychological parameters including depression, 
anxiety and body consciousness and DLQI did not show 
any correlations with age, sex or clinical patterns of 
vitiligo. However, vitiligo patients of younger age (β=  
−0.297, p＜0.05) and with a longer duration of vitiligo 
(β= 0.383, p＜0.05) showed high scores for IAS. Patients 
with exposed lesions or involvement of the face and neck 
did not exhibit increased impairment of psychological 
aspects or QoL. 
Comparison of psychological parameters and quality of 
life among the three groups
In multivariate regression analysis, age and gender affec-
ted several psychological indexes and DLQI (Table 5). 
BDI (β=0.240, p＜0.01), TA (β=0.148, p＜0.05) and 
DLQI (β=0.128, p＜0.05) showed higher values with 
increased age, while IAS showed lower values with age 
(β=−0.228, p＜0.01). In addition, females exhibited 
elevated SA (β=0.164, p＜0.05), TA (β=0.172, p＜ 
0.05) and PBC (β=0.167, p＜0.05), more so than males.
In ANCOVA analysis, vitiligo patients showed increased 
psychological morbidity for TA (p＜0.01), PBC (p＜0.001) 
and DLQI (p＜0.001), compared with NCs (Fig. 1). In 
contrast, vitiligo patients did not show significantly 
elevated scores for BDI (p=0.309) and IAS (p=0.489), 
compared to NCs. All of the psychological parameters as 
well as DLQI were significantly higher in AD patients than 
in NCs. Moreover, in comparison to the vitiligo group, the 
AD group reported significantly higher scores for BDI (p＜ 
0.01), SA (p＜0.05), TA (p＜0.001), IAS (p＜0.01) and 
DLQI (p＜0.001), although there was no significant 
difference in PBC (p=0.797), which reflects internal 
physical sensation and hypochondriatic features. 
DISCUSSION
Vitiligo, characterized by hypopigmented lesions on the 
skin, can cause psychological stress such as depression, 
anxiety and problematic social relations, which can lead 
to significantly impaired QoL. The psychological aspects 
can also modify the course of the illness; for example, 
depression and anxiety can lead to treatment noncom-
pliance and a consequent worsening of vitiligo28. In this 
regard, the psychological effects of vitiligo have been 
copiously described in the literature.
There have been many reports suggesting the negative 
psychological effects of vitiligo. Most of the previous 
studies regarding vitiligo focused on one or two aspects 
among the multiple psychosocial problems, including 
depression, anxiety, low self-esteem, negative experiences 
S Noh, et al
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Fig. 1. Comparison of psychological indexes between normal controls (NCs), vitiligo and atopic dermatitis (AD) groups. Beck depression 
inventory (BDI) (A), state anxiety (SA) (B), trait anxiety (TA) (C), interaction anxiousness scale (IAS) (D), private body consciousness 
(PBC) (E) and Dermatology Life Quality Index (DLQI) (F). All parameters were significantly higher in the atopic dermatitis group 
than in the normal controls. The vitiligo group showed significantly higher TA, PBC and DLQI than the normal controls. IAS was 
elevated in the normal controls compared with the vitiligo group, but was not statistically significant. ns: not significant. *p＜0.05; 
**p＜0.01; ***p＜0.001.
in sexual relationships and impaired QoL2,6-9,29-32. Al-
though there are reports comparing the psychological 
impacts of vitiligo and psoriasis, the psychological aspects 
of skin diseases with and without subjective symptoms 
have rarely been studied, and the psychological aspects of 
vitiligo and AD have been compared in only a few 
studies. In the present study, we compared psychological 
stress in patients with vitiligo, AD patients and NCs using 
questionnaires that evaluated various psychological as-
pects including depression, anxiety, interaction anxious-
ness, body consciousness and QoL. We attempted to 
investigate whether psychological aspects of skin diseases 
Psychological Impacts of Vitiligo and Atopic Dermatitis
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are affected by other accompanying subjective symptoms 
besides the external appearance of the skin lesions.
Sampogna et al.7 reported that the prevalence of depres-
sion in vitiligo patients was higher than that of the general 
Western white population. From our study, depression did 
not appear to be significantly higher in vitiligo patients 
than in NCs. Regarding the prevalence of anxiety in 
vitiligo, various studies have yielded conflicting results. 
Some reports suggested that anxiety was more prevalent in 
vitiligo patients as compared with the general popu-
lation6,7, while Bilgiç et al.29 reported that children and 
adolescents with vitiligo did not show increased levels of 
anxiety compared with controls. In our study, we used 
STAI to evaluate both the situational and general anxiety. 
Patients with vitiligo showed a significantly elevated TA, 
but not SA, than NCs, signifying that vitiligo patients 
experienced a higher level of general anxiety, but not 
situational anxiety. Also, body consciousness was shown 
to be elevated in patients with vitiligo compared to NCs, 
indicating that vitiligo patients were more greatly con-
cerned with the physical appearance and representation.
It might be expected that visible skin lesions would have a 
negative impact on social interactions and QoL, as shown 
in patients (especially women) with visible skin lesions, 
who have been shown to exhibit increased psychiatric 
morbidity33. In the present study, however, social interac-
tion anxiousness as measured by IAS, which related to 
anxiety experienced in social relations and meetings, was 
not influenced by the presence of vitiligo or exposed 
vitiligo lesions, such as on the face and neck. Different 
studies on the impact of the visibility of vitiligo lesions on 
psychosocial difficulties have produced inconsistent 
results7,10,16,31,34,35. The restoration of impaired QoL after 
using cosmetic camouflage implied that the visibility of 
vitiligo lesions had a negative impact on the patients’ 
lives10,34. On the contrary, opposing reports have sugges-
ted that lesion visibility does not affect psychological 
aspects in patients with vitiligo7,31,35. Schmid-Ott et al.35 
reported that the location of vitiligo does not play a critical 
role in the overall stigma and that the presence of vitiligo 
on the face or the hands has been reported to show no 
association with the impaired QoL31. Another study repor-
ted no negative impact of facial lesions on QoL, especially 
in women, presumably because female patients with 
vitiligo can hide facial lesions with cosmetics7. Overall, it 
remains controversial as to whether the visibility of skin 
lesions is critical to psychological morbidity in patients 
with vitiligo. 
DLQI is widely used for assessment of QoL in various skin 
diseases. DLQI scores in vitiligo patients have ranged 3.18 
to 10.67 in different studies10,34,36-38. In this study, the 
mean score of DLQI in vitiligo patients was 7.61, and the 
vitiligo group demonstrated a significantly impaired QoL 
compared with the NC group. As the QoL of patients with 
vitiligo has been reported to be more closely related to the 
patients’ subjective assessment of the disease rather than 
the clinical severity of the condition30, an elevated general 
anxiety and body consciousness in vitiligo patients may 
have contributed to the elevated levels in DLQI, com-
pared to NCs. 
In the analysis of the effects of demographic and clinical 
manifestations on the psychological parameters, all enrol-
led participants of older age showed a lower level of 
interaction anxiousness. This result indicated that older 
patients coped better in the social interactions. However, 
older patients tended to show higher levels of depression, 
anxiety (state and trait) and lower QoL. State and TA, as 
well as body consciousness, were higher among females 
than among males. This finding is consistent with previous 
psychological literature which showed that women ex-
hibit a higher level of anxiety and concerns with physical 
appearance39-41. In the analysis of the vitiligo group, 
vitiligo patients with a longer disease duration reported 
higher values for IAS. While older age is generally 
associated with longer disease duration, the correlation 
between age and disease duration was not observed in 
this study group, which implies that age and disease 
duration affect IAS independently. 
Consistent with previous findings on psychological dist-
ress in patients with AD18,42,43, all psychological para-
meters were significantly higher in the AD group than in 
the NC group in our study. Furthermore, when compared 
with vitiligo, all psychological parameters except for PBC 
were significantly higher in the AD group than in the 
vitiligo group. As a large number of patients with mode-
rate and severe AD are included in this study, the severity 
of AD may have elevated psychological stress and wor-
sened QoL compared with the vitiligo group. Pruritus, a 
main symptom of AD, is known to be related with anxiety 
through neuropeptide Y and nerve growth factor18, and 
may play a critical role in causing psychological stress. 
Considering that vitiligo is not usually accompanied by 
any subjective symptoms such as itching, it may be 
hypothesized that the presence of symptoms such as 
pruritus in AD may have elevated the psychological stress 
and impaired QoL. 
In the case of PBC subscales, which assess attention to 
internal physical sensations and hypochondriatic features, 
the vitiligo patients showed no significant difference from 
AD patients, despite significantly higher values of PBC 
compared with the NC group. Taken together with the 
results for IAS, which was not elevated in vitiligo patients, 
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we suggest that vitiligo patients might be more concerned 
with the spreading or aggravation of the hypopigmented 
lesions on their bodies than the social problems asso-
ciated with unwanted attention from other people. In this 
context, we may assume that non-exposed skin lesions 
can also distress vitiligo patients.
Cross-sectional in nature, this study is limited in that it is 
reflective of the psychological aspects at any given point, 
which may fluctuate in time. Repeated longitudinal stu-
dies may overcome this limitation. Also, by including 
additional factors such as the degree of pruritus and loss of 
sleep in patients with AD, the role of such symptoms in 
elevating psychological stress may be clarified in a further 
study. The comparison of four different psychological 
aspects as well as QoL in patients with vitiligo and AD is a 
unique and distinguishing feature of this study.
In conclusion, the degree of psychological stress and 
impaired QoL may be different in patients with different 
skin diseases depending on the presence of skin symp-
toms. While the patients with vitiligo in this study showed 
less psychological stress and less impaired QoL than AD 
patients, they still exhibited elevated levels of anxiety and 
body consciousness, as well as more impaired QoL in 
comparison to NCs. Also, physicians should be aware that 
even unexposed vitiligo lesions may distress patients, and 
that patients with vitiligo may be more concerned with the 
aggravation of hypopigmented patches on the body, even 
those unexposed, than with difficulties in social interac-
tions. 
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